The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment
Open accessAbstract
Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells, which can be isolated from different types of tissues including bone marrow, adipose tissue, tooth pulp, and placenta/umbilical cord blood. There isolation from adult tissues circumvents the ethical concerns of working with embryonic or fetal stem cells, whilst still providing cells capable of differentiating into various cell lineages, such as adipocytes, osteocytes and chondrocytes. An important feature of MSCs is the low immunogenicity due to the lack of co-stimulatory molecules expression, meaning there is no need for immunosuppression during allogenic transplantation. The tropism of MSCs to damaged tissues and tumor sites makes them a promising vector for therapeutic agent delivery to tumors and metastatic niches. MSCs can be genetically modified by virus vectors to encode tumor suppressor genes, immunomodulating cytokines and their combinations, other therapeutic approaches include MSCs priming/loading with chemotherapeutic drugs or nanoparticles. MSCs derived membrane microvesicles (MVs), which play an important role in intercellular communication, are also considered as a new therapeutic agent and drug delivery vector. Recruited by the tumor, MSCs can exhibit both pro- and anti-oncogenic properties. In this regard, for the development of new methods for cancer therapy using MSCs, a deeper understanding of the molecular and cellular interactions between MSCs and the tumor microenvironment is necessary. In this review, we discuss MSC and tumor interaction mechanisms and review the new therapeutic strategies using MSCs and MSCs derived MVs for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“It is believed that the migration of MSCs toward the tumor is determined by inflammatory signaling similar to a chronic non-healing wound (Dvorak, 1986).”
BackgroundHuman mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 1×
“…cell lines 8-MG-BA, 42-MG-BA and U-118 MG Matuskova et al., 2010 CD/5-FC Drug precursors transformation Subcutaneous model of melanoma or colon cancer Kucerova et al., 2007, 2008 Cal72 (osteosarcoma) xenograft model NguyenThai et al., 2015 NK4 Apoptosis induction, angiogenesis and C-26 lung…”
BackgroundXu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173
Kucerova, L., Matuskova, M., Pastorakova, A., Tyciakova, S., Jakubikova, J., Bohovic, R., Altanerova, V., & Altaner, C. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1239 · Cited by 171
Targeted Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal Stem Cells
Xin, H., Kanehira, M., Mizuguchi, H., Hayakawa, T., Kikuchi, T., Nukiwa, T., & Saijo, Y. (2007) · STEM CELLS · doi:10.1634/stemcells.2006-0461 · Cited by 164 · cited 1×
“…et al., 2016 CX3CL1 Cytotoxic T cells and NK cells activation Mice bearing lung metastases of C26 (colon carcinoma) and B16F10 (skin melanoma) cells Xin et al., 2007 HSV-TK/GCV Drug precursors transformation 9L (glioma) xenograft model Uchibori et al., 2009 In vitro glioma cell lines 8-MG-BA,…”
BackgroundPinilla, S., Alt, E., Abdul Khalek, F. J., Jotzu, C., Muehlberg, F., Beckmann, C., & Song, Y.-H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.013 · Cited by 156
Honoki, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1220 · Cited by 90
Cited by
Adipose-derived stem cells: Sources, potency, and implications for regenerative therapies
Si, Z., Wang, X., Sun, C., Kang, Y., Xu, J., Wang, X., & Hui, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108765 · Cited by 423
Zhuang, W.-Z., Lin, Y.-H., Su, L.-J., Wu, M.-S., Jeng, H.-Y., Chang, H.-C., Huang, Y.-H., & Ling, T.-Y. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00725-7 · Cited by 258
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
Cell Culture Based in vitro Test Systems for Anticancer Drug Screening
Kitaeva, K. V., Rutland, C. S., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00322 · Cited by 142
Self-citationExtracellular vesicles remodel tumor environment for cancer immunotherapy
Yue, M., Hu, S., Sun, H., Tuo, B., Jia, B., Chen, C., Wang, W., Liu, J., Liu, Y., Sun, Z., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01898-5 · Cited by 119
Kitaeva, K. V., Solovyeva, V. V., Blatt, N. L., & Rizvanov, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010643 · Cited by 7
Self-citation
Metadata
- Authors
- Chulpanova, D. S., Kitaeva, K. V., Tazetdinova, L. G., James, V., Rizvanov, A. A., & Solovyeva, V. V.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-20
- Volume
- 9
- Pages
- 259-259
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2790571094
- Cited by
- 171
- References
- 15
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.